| |
Thursday, December 8, 2022 | 11am ET/8am PT QWBA studies are conducted to determine the distribution of total radioactivity into tissues of pigmented animals who are administered a single dose of a radiolabeled drug candidate. Learn about the benefits of QWBA studies, including why a QWBA study is essential to ensure the safety of human subjects. Register now. 
|
|
|
Thursday, December 8, 2022 | 2:00pm ET / 11:00am PT In this webinar, a group of experts will sit on this engaging panel discussion to examine the state of analytical characterization today, current regulatory guidance, best practices, and forward-looking considerations in early drug development that can lead to process improvement in the hopes of mitigating clinical holds. Register now! 
|
|
| By Nick Paul Taylor Roche has shared the data that it hopes will secure approval for a subcutaneous formulation of its PD-L1 checkpoint inhibitor Tecentriq. Having revealed the topline success in August, the Swiss drugmaker will use ESMO Immuno-Oncology Congress 2022 to show off the figures behind the co-primary endpoint hits. |
|
|
|
By Nick Paul Taylor Vaxxas has secured funding to support clinical development of its needle-free COVID-19 vaccine, stuffing its coffers with $23 million from investors including OneVentures and UniQuest. |
By Nick Paul Taylor PureTech Health has spied an opportunity to improve on Jazz Pharmaceuticals’ Epidiolex. Armed with its Glyph chemistry platform, the biotech has created an oral capsule formulation of cannabidiol that it plans to take into the clinic late next year. |
By Nick Paul Taylor Investors have boosted Re-Vana Therapeutics’ ambition to develop sustained-release eye disease drugs, putting up $11.9 million in series A funding on the back of nonclinical ocular safety and efficacy studies. |
|
Thursday, December 8, 2022 | 2:00pm ET / 11:00am PT In this webinar, a group of experts will sit on this engaging panel discussion to examine the state of analytical characterization today, current regulatory guidance, best practices, and forward-looking considerations in early drug development that can lead to process improvement in the hopes of mitigating clinical holds. Register now! 
|
|
By Max Bayer Dermata Therapeutics' rosacea ambitions are in the red after the company’s lead asset failed a phase 2 trial, placing additional pressure on the med as an acne treatment. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the current state of Biogen and recent investor reactions to the new hire. Plus we cover the week's news including: What Albert Bourla said that has him in hot water, a $3.5 million drug, and we tease a possible major acquisition. |
|
|---|
|
|
|
This playbook looks at why insolubility is an issue, and the properties that affect solubility, such as the molecule’s structure; its physical attributes (particle size and dissolution rate); its chemical attributes, including compatibility with excipients; and its biological properties. Download now. 
|
|
Multimedia Plan Your ASH’22 Attendance In No Time | Interactive Planner Sponsored by: Ferma.AI, a product of ZoomRx |
Podcast How can Medical Affairs divisions bring greater value to their organizations and practitioners every day? Sponsored by: Medscape Medical Affairs |
eBook See how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more. Sponsored by: Health Catalyst |
Whitepaper Accelerating bioproduction towards high performance and scale Sponsored by: Capgemini Americas Inc. |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Sponsored by: Catalent |
| |
|
